机构：[1]Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510630, China.[2]Affiliated Huaqiao Hospital, Jinan University, Guangzhou 510630, China.[3]Department of Pathophysiology, Key Laboratory of State Administration of Traditional Chinese Medicine of the People's Republic of China, School of Medicine, Jinan University, Guangzhou 510630, China.[4]Department of Systems Biomedical Sciences, School of Medicine, Jinan University, Guangzhou 510630, China.[5]Department of Food Science and Engineering, Institute of Food Safety and Nutrition, Guangdong Engineering Technology Center of Food Safety Molecular Rapid Detection, Jinan University, Guangzhou 510630, China.[6]Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen 518000, China.[7]Jinan University-BioKangtai Vaccine Institute, School of Medicine, Jinan University, Guangzhou 510630, China.
As the COVID-19 epidemic progresses with the emergence of different SARS-CoV-2 variants, it is important to know the effectiveness of inactivated SARS-CoV-2 vaccines against the variants. To maximize efficiency, a third boost injection of the high-dose SARS-CoV-2 inactivated vaccine KCONVAC was selected for investigation. In addition to the ancestral strain, KCONVAC boost vaccination induced neutralizing antibodies and antigen-specific CD8 T cells to recognize several variants, including B.1.617.2 (Delta), B.1.1.529 (Omicron), B.1.1.7 (Alpha), B.1.351 (Beta), P.3, B.1.526.1 (Lota), B.1.526.2, B.1.618, and B.1.617.3. Both humoral and cellular immunity against variants were lower than those of ancestral variants but continued to increase from day 0 to day 7 to day 50 after boost vaccination. Fifty days post-boost, the KCONVAC-vaccinated CD8 T-cell level reached 1.23-, 2.59-, 2.53-, and 1.01-fold that of convalescents against ancestral, Delta, Omicron and other SARS-CoV-2 variants, respectively. Our data demonstrate the importance of KCONVAC boosters to broaden both humoral and cellular immune responses against SARS-CoV-2 variants.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|3 区医学
小类|3 区病毒学
最新[2025]版：
大类|3 区医学
小类|3 区病毒学
第一作者：
第一作者机构：[1]Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510630, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou 510630, China.[7]Jinan University-BioKangtai Vaccine Institute, School of Medicine, Jinan University, Guangzhou 510630, China.
推荐引用方式(GB/T 7714)：
Xiao Chanchan,Su Jun,Zhang Chanjuan,et al.Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains[J].Viruses.2022,14(9):doi:10.3390/v14092016.
APA：
Xiao Chanchan,Su Jun,Zhang Chanjuan,Huang Boya,Mao Lipeng...&Qiu Congling.(2022).Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains.Viruses,14,(9)
MLA：
Xiao Chanchan,et al."Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains".Viruses 14..9(2022)
